Nav: Home

Chemotherapy or not?

April 24, 2019

CLEVELAND--Case Western Reserve University researchers and partners, including a collaborator at Cleveland Clinic, are pushing the boundaries of how "smart" diagnostic-imaging machines identify cancers--and uncovering clues outside the tumor to tell whether a patient will respond well to chemotherapy.

The recent findings in breast and lung cancer research build off work pioneered by biomedical engineering professor Anant Madabhushi, founder of the Center for Computational Imaging and Personalized Diagnostics. He is senior author on a pair of recent journal publications and joined by scientists from the Case School of Engineering, Cleveland Clinic and New York University Langone Medical Center.

This work, in total, heralds a more personalized future in medical diagnoses, Madabhushi said.

"And it is further evidence that information gleaned by computational interrogation of the region outside the tumors on MRI (magnetic resonance images) and CAT (computed tomography) scans is extremely valuable and can predict response and benefit of chemotherapy in lung and breast cancer patients," said Madabhushi, the F. Alex Nason Professor II of Biomedical Engineering at the Case School of Engineering.

Madabhushi founded the center in 2012 and has more than 50 collaborators working on related projects. The lab has become a global leader in the detection, diagnosis and characterization of various cancers and other diseases by meshing medical imaging, machine learning and artificial intelligence.

Hope for HER2 breast cancer

The most recent research--published April 19 in JAMA Network Open--focuses on markers on tissue outside a breast tumor that can indicate whether a patient will respond to targeted chemotherapy.

Biomedical Engineering doctoral researcher Nathaniel Braman and medical school faculty member Vinay Varadan led a team of collaborators who reported discovery of a previously hidden "signature" associated with one type of breast cancer, known as HER2-positive (or simply HER2). It comprises about 20% of all cases and receives a special targeted treatment strategy.

The researchers have been able to classify the patients with HER2 breast cancer into molecular subtypes--corresponding to those who will likely respond to targeted chemotherapy and those who won't--simply by analyzing an initial tissue sample.

The work "provides insights into the ability of radiomic analyses to capture clinically-significant tumor biology," explained Varadan, a co-senior author on the study with Madabhushi. It "justifies additional studies to assess the clinical utility of such noninvasive approaches to guide therapeutic strategies in this disease."

The markers are not found on images made from tissue slides, but outside the tumor itself. They cannot be seen by the human eye, but are revealed by a process known as radiomics, which extracts relevant data from medical images like MRIs.

"Right now, these patients receive 'one-size-fits-all' treatment despite being quite diverse," Braman said. "What we're trying to do here is identify before treatment which patients will actually benefit from specific therapies. This could give doctors and patients information they did not have before."

Putting the idea into use is probably years away, following clinical trials and then the big step of someday "getting doctors to be able to trust and use it," Braman said.

To that end, the researchers wrote that they explored the overlap between their imaging signature and information from the tissue slides and genetics that doctors consider important in treatment decisions.

Radiomics of region outside lung nodule predicts benefit of chemotherapy

The other study, published in March, also evaluates whether computer-extracted image patterns (or radiomics) outside a tumor can indicate whether a lung cancer patient will respond to targeted chemotherapy.

"The problem at the start is that only one in four lung cancer patients will respond favorably to chemotherapy, but virtually everyone gets that treatment," said biomedical engineering doctoral researcher Mohammadhadi Khorrami, one of the leaders of the research. "But all of the previous research has been limited to inside the tumor."

In this case, the researchers examined image data from 125 Cleveland Clinic patients diagnosed with non-small cell lung cancer (NSCLC). All had previously received targeted chemotherapy, but only about half had responded to the difficult treatment.

Using the information gleaned from those patients' data, researchers trained their technology to distinguish between image data of patients who had responded and those who had not. Then they tested the technology against additional patient data.

"By looking both inside and outside the tumor," Khorrami said, "we achieved an accuracy of 77% in determining which patients would benefit from chemotherapy--far better (68%) than just looking at the tumor itself."

Khorrami was the first author of a team of 10 researchers who published the research with Monica Khunger, a Cleveland Clinic physician at the time of the study, now employed by UPMC in Pittsburgh.) Their work appeared in March in the journal Radiology: Artificial Intelligence.

Using radiomics, researchers can extract quantitative, or measurable, data from CT images that can reveal disease characteristics not visible in the images alone, according to a Radiological Society of America's news release on the research.

"This can change the game, not only for the patient when it comes to outcome, but when it comes to cost overall for the health-care field," Khorrami said. "It costs about $30,000 or more a year for chemotherapy, so it's important to know who will respond to chemotherapy, and we're getting closer to a true biomarker to do that."
Case Western Reserve University is one of the country's leading private research institutions. Located in Cleveland, we offer a unique combination of forward-thinking educational opportunities in an inspiring cultural setting. Our leading-edge faculty engage in teaching and research in a collaborative, hands-on environment. Our nationally recognized programs include arts and sciences, dental medicine, engineering, law, management, medicine, nursing and social work. About 5,100 undergraduate and 6,700 graduate students comprise our student body. Visit to see how Case Western Reserve thinks beyond the possible.

Case Western Reserve University

Related Breast Cancer Articles:

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.
Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.
Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.
More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.
Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.
Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.
Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.
Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.
Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.
Does MRI plus mammography improve detection of new breast cancer after breast conservation therapy?
A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
More Breast Cancer News and Breast Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Our Relationship With Water
We need water to live. But with rising seas and so many lacking clean water – water is in crisis and so are we. This hour, TED speakers explore ideas around restoring our relationship with water. Guests on the show include legal scholar Kelsey Leonard, artist LaToya Ruby Frazier, and community organizer Colette Pichon Battle.
Now Playing: Science for the People

#569 Facing Fear
What do you fear? I mean really fear? Well, ok, maybe right now that's tough. We're living in a new age and definition of fear. But what do we do about it? Eva Holland has faced her fears, including trauma and phobia. She lived to tell the tale and write a book: "Nerve: Adventures in the Science of Fear".
Now Playing: Radiolab

First things first: our very own Latif Nasser has an exciting new show on Netflix. He talks to Jad about the hidden forces of the world that connect us all. Then, with an eye on the upcoming election, we take a look back: at two pieces from More Perfect Season 3 about Constitutional amendments that determine who gets to vote. Former Radiolab producer Julia Longoria takes us to Washington, D.C. The capital is at the heart of our democracy, but it's not a state, and it wasn't until the 23rd Amendment that its people got the right to vote for president. But that still left DC without full representation in Congress; D.C. sends a "non-voting delegate" to the House. Julia profiles that delegate, Congresswoman Eleanor Holmes Norton, and her unique approach to fighting for power in a virtually powerless role. Second, Radiolab producer Sarah Qari looks at a current fight to lower the US voting age to 16 that harkens back to the fight for the 26th Amendment in the 1960s. Eighteen-year-olds at the time argued that if they were old enough to be drafted to fight in the War, they were old enough to have a voice in our democracy. But what about today, when even younger Americans are finding themselves at the center of national political debates? Does it mean we should lower the voting age even further? This episode was reported and produced by Julia Longoria and Sarah Qari. Check out Latif Nasser's new Netflix show Connected here. Support Radiolab today at